What is Myelofibrosis

Myelofibrosis is a rare type of chronic blood cancer where excessive scar tissue forms in the bone marrow, disrupting the body's ability to produce healthy blood cells. This condition, which belongs to a group of disorders known as myeloproliferative neoplasms, often leads to anemia, fatigue, and an enlarged spleen.

What exactly happens in the body with Myelofibrosis?

In a healthy body, bone marrow acts as a factory for blood cells. In patients with Myelofibrosis, genetic mutations cause the marrow to become inflamed and eventually replaced by fibrous, scar-like tissue. As the marrow fails, the body attempts to produce blood cells in other organs, such as the liver and spleen, causing them to enlarge (splenomegaly). This process, known as extramedullary hematopoiesis, is a hallmark of Myelofibrosis.

How common is Myelofibrosis and who is affected?

Myelofibrosis is considered a rare disease, with an estimated incidence of approximately 1 in 100,000 people per year. While it can occur at any age, it is most frequently diagnosed in individuals over the age of 60. It affects both men and women, with no specific geographic, ethnic, or racial predilection identified in current clinical literature.

How is Myelofibrosis classified?

Clinicians typically categorize Myelofibrosis into two distinct types:

• Primary Myelofibrosis: This occurs on its own, without a prior history of other blood disorders.


• Secondary Myelofibrosis: This develops as a progression from other myeloproliferative neoplasms, such as polycythemia vera or essential thrombocythemia.

What differentiates this condition from other blood disorders?

Unlike leukemia, which is often characterized by the rapid overproduction of immature white blood cells, Myelofibrosis is defined primarily by the progressive scarring of the bone marrow architecture. Our DiseaseMaps.org community currently includes 16 members who share their unique experiences navigating these challenges, providing a vital support network for those adjusting to a new diagnosis.

Next steps

• Consult a hematologist or an oncologist who specializes in myeloproliferative neoplasms (MPNs).


• Request a bone marrow biopsy and genetic testing (such as JAK2, CALR, or MPL mutation analysis) to confirm the diagnosis.


• Join the DiseaseMaps.org community to connect with others living with Myelofibrosis.


• Discuss potential clinical trials or targeted therapies, such as JAK inhibitors, with your care team.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD) - Myelofibrosis.


• Orphanet: Primary myelofibrosis (ORPHA:593).


• MPN Research Foundation - Understanding Myelofibrosis.


• National Cancer Institute (NCI) - Myeloproliferative Neoplasms Treatment.